The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.9M data for 1.2M Compounds and 9.3K Targets. Of those, 1,352K data for 627K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

36 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Synthetic 1,2,3-triazole-linked glycoconjugates bind with high affinity to human galectin-3.EBI
Fcfrp - Usp
Synthesis and evaluation of iminocoumaryl and coumaryl derivatized glycosides as galectin antagonists.EBI
Lund University
Elements and modulation of functional dynamics.EBI
Janssen Research and Development
Tuning the preference of thiodigalactoside- and lactosamine-based ligands to galectin-3 over galectin-1.EBI
Utrecht University
1H-1,2,3-triazol-1-yl thiodigalactoside derivatives as high affinity galectin-3 inhibitors.EBI
The Hashemite University
Galectin-inhibitory thiodigalactoside ester derivatives have antimigratory effects in cultured lung and prostate cancer cells.EBI
Lund University
Synthesis of stable and selective inhibitors of human galectins-1 and -3.EBI
Universit£
Synthesis and galectin-binding activities of mercaptododecyl glycosides containing a terminalß-galactosyl group.EBI
National Institute of Advanced Industrial Science and Technology (Aist)
Protein subtype-targeting through ligand epimerization: talose-selectivity of galectin-4 and galectin-8.EBI
Lund University
Novel Selective Galectin-3 Antagonists Are Cytotoxic to Acute Lymphoblastic Leukemia.EBI
Griffith University
Identification of Monosaccharide Derivatives as Potent, Selective, and Orally Bioavailable Inhibitors of Human and Mouse Galectin-3.EBI
Bristol Myers Squibb
Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease.EBI
Galecto Biotech
Synthesis, Structure-Activity Relationships, and In Vivo Evaluation of Novel Tetrahydropyran-Based Thiodisaccharide Mimics as Galectin-3 Inhibitors.EBI
Bristol Myers Squibb
Benzimidazole-galactosides bind selectively to the Galectin-8 N-Terminal domain: Structure-based design and optimisation.EBI
Lund University
Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain.EBI
Lund University
Quinoline-Pyrazole Scaffold as a Novel Ligand of Galectin-3 and Suppressor of TREM2 Signaling.EBI
Stanford University School of Medicine
Novel Galectin-3 Inhibitors for Treating Fibrosis.EBI
Smith, Gambrell & Russell
A Selective Galactose-Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model.EBI
Institute of Science Education and Research-Kolkata (Iiser) Kolkata
Epimers Switch Galectin-9 Domain Selectivity: 3EBI
Lund University
Binding of triazole-linked galactosyl arylsulfonamides to galectin-3 affects Trypanosoma cruzi cell invasion.EBI
University of Sao Paulo
Systematic Tuning of Fluoro-galectin-3 Interactions Provides Thiodigalactoside Derivatives with Single-Digit nM Affinity and High Selectivity.EBI
Lund University